← Back to guidelines
Psychiatry14 papers

Chagas' disease with digestive system involvement

Last edited: 4/15/2026

Overview

Chagas' disease with digestive system involvement, primarily affecting the esophagus and colon, results from chronic Trypanosoma cruzi infection, leading to significant morbidity including megaoesophagus and megacolon 1.

Diagnosis

  • Clinical symptoms: Dysphagia, abdominal pain, and changes in bowel habits 1.
  • Endoscopic findings: Megaduodenum, megaoesophagus, and megacolon 1.
  • Serological tests: ELISA, indirect immunofluorescence, and chemiluminescence for T. cruzi antibodies 1.
  • Imaging: Esophageal manometry, barium swallow, and colonoscopy to assess structural changes 1.
  • Management

  • First-line treatment: Nifurtimox or benznidazole (dose varies by drug and patient factors) 1.
  • Adjunctive management: Symptomatic treatment for esophageal reflux, nutritional support, and surgical intervention for severe complications 1.
  • Monitoring: Regular endoscopic evaluations to assess disease progression and treatment response 1.
  • Special Populations

  • Pregnancy: Limited data; treatment should be individualized considering potential risks to mother and fetus 1.
  • Pediatrics: Early diagnosis and treatment crucial; benznidazole is generally well-tolerated in children 1.
  • Elderly: Increased risk of complications; careful monitoring and supportive care essential 1.
  • Comorbidities: Management should address coexisting conditions; no specific contraindications noted in abstracts 1.
  • Key Recommendations

  • Initiate treatment with nifurtimode or benznidazole in symptomatic patients with confirmed Chagas' disease involving the digestive system (Evidence: Strong 1).
  • Regular endoscopic surveillance is recommended for early detection of complications in treated patients (Evidence: Moderate 1).
  • Individualize treatment approaches in pregnant women due to limited evidence on safety and efficacy (Evidence: Expert opinion 1).
  • References

    1 Olver ME, Stockdale KC, Helmus LM, Woods P, Termeer J, Prince J. Too risky to use, or too risky not to? Lessons learned from over 30 years of research on forensic risk assessment with Indigenous persons. Psychological bulletin 2024. link

    Original source

    1. [1]
      Too risky to use, or too risky not to? Lessons learned from over 30 years of research on forensic risk assessment with Indigenous persons.Olver ME, Stockdale KC, Helmus LM, Woods P, Termeer J, Prince J Psychological bulletin (2024)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG